Prognosis
Astra Shot Shows 82% Efficacy With U.K.’s Two-Dose Interval
- Findings bolster case for U.K.’s controversial dosing regime
- Shot also led to significant reduction in virus transmission
This article is for subscribers only.
AstraZeneca Plc’s Covid vaccine showed 82% effectiveness with a three-month gap between two shots, according to a new study that bolsters the U.K.’s controversial decision to adopt an extended dosing interval.
The vaccine may also significantly reduce transmission of the virus, according to analysis of trial data by the University of Oxford, which developed the shot with the British drugmaker. Swabs taken from volunteers in the U.K. arm of the trial showed a 67% reduction in transmission after the first dose, the report showed.